[
    {
        "study_id": "NCT00638690",
        "nct_id": "NCT00638690",
        "studyTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00887198",
        "nct_id": "NCT00887198",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-10-31T14:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00924469",
        "nct_id": "NCT00924469",
        "studyTitle": "A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-28T19:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01424930",
        "nct_id": "NCT01424930",
        "studyTitle": "An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-28T19:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01314118",
        "nct_id": "NCT01314118",
        "studyTitle": "A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-08T12:06:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01695135",
        "nct_id": "NCT01695135",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:46:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02236637",
        "nct_id": "NCT02236637",
        "studyTitle": "A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-08-12T15:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00485303",
        "nct_id": "NCT00485303",
        "studyTitle": "A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:38:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01685983",
        "nct_id": "NCT01685983",
        "studyTitle": "A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00474383",
        "nct_id": "NCT00474383",
        "studyTitle": "A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:43:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00473746",
        "nct_id": "NCT00473746",
        "studyTitle": "Phase I/II Open Label Dose Escalation Study of the 17\u03b1-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01795703",
        "nct_id": "NCT01795703",
        "studyTitle": "A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00544440",
        "nct_id": "NCT00544440",
        "studyTitle": "An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01867710",
        "nct_id": "NCT01867710",
        "studyTitle": "A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-na\u00efve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-23T14:55:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01088529",
        "nct_id": "NCT01088529",
        "studyTitle": "A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-28T19:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01715285",
        "nct_id": "NCT01715285",
        "studyTitle": "A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T12:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01381874",
        "nct_id": "NCT01381874",
        "studyTitle": "Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-04-13T13:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01591122",
        "nct_id": "NCT01591122",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-10-15T12:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00473512",
        "nct_id": "NCT00473512",
        "studyTitle": "A Phase I/II Open Label Study of the 17\u03b1-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01385202",
        "nct_id": "NCT01385202",
        "studyTitle": "THERMOCOOL\u00ae SMARTTOUCH\u2122 Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-04-27T10:07:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04436276",
        "nct_id": "NCT04436276",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-01-24T18:57:56+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04505722",
        "nct_id": "NCT04505722",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-01-24T19:03:26+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04614948",
        "nct_id": "NCT04614948",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-01-24T19:08:23+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03060629",
        "nct_id": "NCT03060629",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-05-06T18:48:26+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02926430",
        "nct_id": "NCT02926430",
        "studyTitle": "A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:10:32+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03502707",
        "nct_id": "NCT03502707",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older",
        "overallStatus": "",
        "phase": "Phase1, 2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:15:55+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04354480",
        "nct_id": "NCT04354480",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Single Vaccination of an Ad26.RSV.preF-based Regimen in Japanese Adults Aged 60 Years and Older",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:25:53+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03982199",
        "nct_id": "NCT03982199",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:38:56+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03334695",
        "nct_id": "NCT03334695",
        "studyTitle": "An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:47:20+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03339713",
        "nct_id": "NCT03339713",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T18:57:45+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04453202",
        "nct_id": "NCT04453202",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels of an Ad26.RSV.preF-based Vaccine in Adults Aged 60 Years and Older",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T19:06:52+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT05101486",
        "nct_id": "NCT05101486",
        "studyTitle": "A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T19:13:36+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT05083585",
        "nct_id": "NCT05083585",
        "studyTitle": "A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 Years",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T19:20:16+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT05071313",
        "nct_id": "NCT05071313",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T19:28:54+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT05070546",
        "nct_id": "NCT05070546",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-18T19:38:21+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02257736",
        "nct_id": "NCT02257736",
        "studyTitle": "A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-11-23T15:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02489318",
        "nct_id": "NCT02489318",
        "studyTitle": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01946204",
        "nct_id": "NCT01946204",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01790126",
        "nct_id": "NCT01790126",
        "studyTitle": "The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-03-06T21:55:26+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00575055",
        "nct_id": "NCT00575055",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer\u2019s Disease Who Are Apolipoprotein E4 Carriers",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T12:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00574132",
        "nct_id": "NCT00574132",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer\u2019s Disease Who Are Apolipoprotein E4 Non- Carriers",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T13:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00449644",
        "nct_id": "NCT00449644",
        "studyTitle": "A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-05-15T15:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00910871",
        "nct_id": "NCT00910871",
        "studyTitle": "A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-05-15T15:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00523926",
        "nct_id": "NCT00523926",
        "studyTitle": "An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-naive Subjects With Sputum Smear Positive Pulmonary Tuberculosis.",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-27T16:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04019041",
        "nct_id": "NCT04019041",
        "studyTitle": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04021862",
        "nct_id": "NCT04021862",
        "studyTitle": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00391443",
        "nct_id": "NCT00391443",
        "studyTitle": "Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis \u2013 a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-09-10T12:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00319111",
        "nct_id": "NCT00319111",
        "studyTitle": "Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-05-20T16:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00303459",
        "nct_id": "NCT00303459",
        "studyTitle": "Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension \u2013 A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-05-20T16:44:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00433329",
        "nct_id": "NCT00433329",
        "studyTitle": "COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-05-20T16:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00091715",
        "nct_id": "NCT00091715",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-05-20T16:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01009177",
        "nct_id": "NCT01009177",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T11:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00071461",
        "nct_id": "NCT00071461",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T14:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00631475",
        "nct_id": "NCT00631475",
        "studyTitle": "Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T14:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00070590",
        "nct_id": "NCT00070590",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T15:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00077584",
        "nct_id": "NCT00077584",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T16:05:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00319033",
        "nct_id": "NCT00319033",
        "studyTitle": "Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-11-27T16:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00319267",
        "nct_id": "NCT00319267",
        "studyTitle": "An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T13:03:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00313222",
        "nct_id": "NCT00313222",
        "studyTitle": "Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T14:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00319020",
        "nct_id": "NCT00319020",
        "studyTitle": "An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T15:05:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01223352",
        "nct_id": "NCT01223352",
        "studyTitle": "An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T15:25:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01338415",
        "nct_id": "NCT01338415",
        "studyTitle": "A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T15:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00319696",
        "nct_id": "NCT00319696",
        "studyTitle": "Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T16:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00642278",
        "nct_id": "NCT00642278",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:11:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01106625",
        "nct_id": "NCT01106625",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01064414",
        "nct_id": "NCT01064414",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01081834",
        "nct_id": "NCT01081834",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01106677",
        "nct_id": "NCT01106677",
        "studyTitle": "A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:17:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00968812",
        "nct_id": "NCT00968812",
        "studyTitle": "A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:18:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01106651",
        "nct_id": "NCT01106651",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:20:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01106690",
        "nct_id": "NCT01106690",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01137812",
        "nct_id": "NCT01137812",
        "studyTitle": "A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01809327",
        "nct_id": "NCT01809327",
        "studyTitle": "A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-10-26T16:14:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01381900",
        "nct_id": "NCT01381900",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-10-26T16:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01340664",
        "nct_id": "NCT01340664",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-10-26T16:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02025907",
        "nct_id": "NCT02025907",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-10-26T16:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01989754",
        "nct_id": "NCT01989754",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-08-12T15:10:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00650806",
        "nct_id": "NCT00650806",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T13:08:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02243202",
        "nct_id": "NCT02243202",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-12-12T13:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01032629",
        "nct_id": "NCT01032629",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02065791",
        "nct_id": "NCT02065791",
        "studyTitle": "A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03267576",
        "nct_id": "NCT03267576",
        "studyTitle": "Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-02-15T17:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02139943",
        "nct_id": "NCT02139943",
        "studyTitle": "A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T14:17:33+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03548207",
        "nct_id": "NCT03548207",
        "studyTitle": "A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-03-01T21:00:04+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02076009",
        "nct_id": "NCT02076009",
        "studyTitle": "Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-09-07T15:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02136134",
        "nct_id": "NCT02136134",
        "studyTitle": "Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-09-07T15:32:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01985126",
        "nct_id": "NCT01985126",
        "studyTitle": "An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-03-22T10:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02252172",
        "nct_id": "NCT02252172",
        "studyTitle": "A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T12:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03180736",
        "nct_id": "NCT03180736",
        "studyTitle": "A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-26T16:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02195479",
        "nct_id": "NCT02195479",
        "studyTitle": "A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-26T17:00:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03277105",
        "nct_id": "NCT03277105",
        "studyTitle": "A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03412565",
        "nct_id": "NCT03412565",
        "studyTitle": "A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01998971",
        "nct_id": "NCT01998971",
        "studyTitle": "An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02951819",
        "nct_id": "NCT02951819",
        "studyTitle": "Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00574288",
        "nct_id": "NCT00574288",
        "studyTitle": "Daratumumab (HuMax\u00ae-CD38) Safety Study in Multiple Myeloma \u2013 Open Label, Dose-escalation Followed by Open Label, Single-arm Study",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01615029",
        "nct_id": "NCT01615029",
        "studyTitle": "An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:46:07+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02874742",
        "nct_id": "NCT02874742",
        "studyTitle": "Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-10-29T01:21:32+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00071097",
        "nct_id": "NCT00071097",
        "studyTitle": "A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-07-27T15:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00650832",
        "nct_id": "NCT00650832",
        "studyTitle": "A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Subjects, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-07-27T15:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00258557",
        "nct_id": "NCT00258557",
        "studyTitle": "Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-07-27T15:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00919854",
        "nct_id": "NCT00919854",
        "studyTitle": "A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-07-31T10:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00915655",
        "nct_id": "NCT00915655",
        "studyTitle": "A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-07-31T11:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00355524",
        "nct_id": "NCT00355524",
        "studyTitle": "A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-07-31T15:09:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02269917",
        "nct_id": "NCT02269917",
        "studyTitle": "A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-07-27T05:12:24+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02431247",
        "nct_id": "NCT02431247",
        "studyTitle": "A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-07-27T05:12:24+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02472145",
        "nct_id": "NCT02472145",
        "studyTitle": "A Randomized Phase 2/3 Study of DACOGEN\u00ae (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-11-21T15:22:45+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00653952",
        "nct_id": "NCT00653952",
        "studyTitle": "A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX\u00ae versus Paclitaxel HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-11-19T09:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00211133",
        "nct_id": "NCT00211133",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00270127",
        "nct_id": "NCT00270127",
        "studyTitle": "Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving non-Platinum-Containing Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:38:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00270166",
        "nct_id": "NCT00270166",
        "studyTitle": "A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00270049",
        "nct_id": "NCT00270049",
        "studyTitle": "The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:43:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00270101",
        "nct_id": "NCT00270101",
        "studyTitle": "A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:46:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00270283",
        "nct_id": "NCT00270283",
        "studyTitle": "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:48:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00091910",
        "nct_id": "NCT00091910",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210626",
        "nct_id": "NCT00210626",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT\u00ae)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-01-12T17:46:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00269997",
        "nct_id": "NCT00269997",
        "studyTitle": "The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-10T12:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00266617",
        "nct_id": "NCT00266617",
        "studyTitle": "The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-10T12:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01394991",
        "nct_id": "NCT01394991",
        "studyTitle": "A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T09:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00211146",
        "nct_id": "NCT00211146",
        "studyTitle": "An Open-Label, Randomized, Parallel-Group Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Subjects Undergoing Major Elective Spinal Surgery",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T17:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00211120",
        "nct_id": "NCT00211120",
        "studyTitle": "Correction of Hemoglobin and Outcomes In Renal Insufficiency (CHOIR)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-04-25T13:32:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02365597",
        "nct_id": "NCT02365597",
        "studyTitle": "An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-09-05T14:42:22+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03390504",
        "nct_id": "NCT03390504",
        "studyTitle": "A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-04-29T20:54:04+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02417064",
        "nct_id": "NCT02417064",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-01T12:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02418585",
        "nct_id": "NCT02418585",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-01T13:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02422186",
        "nct_id": "NCT02422186",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-01T13:27:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03039192",
        "nct_id": "NCT03039192",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-01T19:37:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02133001",
        "nct_id": "NCT02133001",
        "studyTitle": "A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-04T15:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03097133",
        "nct_id": "NCT03097133",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-03-04T15:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02497287",
        "nct_id": "NCT02497287",
        "studyTitle": "An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02493868",
        "nct_id": "NCT02493868",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01998958",
        "nct_id": "NCT01998958",
        "studyTitle": "A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02918318",
        "nct_id": "NCT02918318",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01627782",
        "nct_id": "NCT01627782",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01640080",
        "nct_id": "NCT01640080",
        "studyTitle": "A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03434041",
        "nct_id": "NCT03434041",
        "studyTitle": "A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-09T22:12:42+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04338321",
        "nct_id": "NCT04338321",
        "studyTitle": "A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/\u200bSerotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-06-23T21:11:46+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01466673",
        "nct_id": "NCT01466673",
        "studyTitle": "Comparative Study of the Effect on Acne With norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T17:11:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01876966",
        "nct_id": "NCT01876966",
        "studyTitle": "A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-04-29T16:05:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253201",
        "nct_id": "NCT00253201",
        "studyTitle": "Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-01-30T12:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00304629",
        "nct_id": "NCT00304629",
        "studyTitle": "Long Term Safety and Efficacy of Galantamine in Alzheimer\u2019s Disease (Extension INT-8)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-01-30T12:14:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253227",
        "nct_id": "NCT00253227",
        "studyTitle": "Galantamine in the Treatment of Alzheimer\u2019s Disease: Flexible Dose Range Trial",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-01-30T12:18:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216502",
        "nct_id": "NCT00216502",
        "studyTitle": "Long Term Treatment With Galantamine In Dementia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-02-10T10:25:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00261573",
        "nct_id": "NCT00261573",
        "studyTitle": "The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-08T16:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253188",
        "nct_id": "NCT00253188",
        "studyTitle": "Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-08T16:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253214",
        "nct_id": "NCT00253214",
        "studyTitle": "Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer\u2019s Disease: Safety and Efficacy of a Controlled-Release Formulation",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-08T16:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236574",
        "nct_id": "NCT00236574",
        "studyTitle": "A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-08T16:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236431",
        "nct_id": "NCT00236431",
        "studyTitle": "A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-08T16:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00679627",
        "nct_id": "NCT00679627",
        "studyTitle": "A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-08-03T14:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216593",
        "nct_id": "NCT00216593",
        "studyTitle": "Treatment of Severe Alzheimer\u2019s Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-03-30T16:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00645190",
        "nct_id": "NCT00645190",
        "studyTitle": "A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer\u2019s Disease:Safety and Effectiveness of an Immediate-release Table Formulation.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-09-07T16:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00082602",
        "nct_id": "NCT00082602",
        "studyTitle": "Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-09-20T16:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00264537",
        "nct_id": "NCT00264537",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-na\u00efve Subjects with Active Rheumatoid Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00264550",
        "nct_id": "NCT00264550",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00265083",
        "nct_id": "NCT00265083",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00299546",
        "nct_id": "NCT00299546",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti TNFa Agent(s)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:59:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00361335",
        "nct_id": "NCT00361335",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T11:01:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00487539",
        "nct_id": "NCT00487539",
        "studyTitle": "A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T11:06:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01248780",
        "nct_id": "NCT01248780",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T11:10:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01248793",
        "nct_id": "NCT01248793",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects with Ankylosing Spondylitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T11:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00265096",
        "nct_id": "NCT00265096",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-07-28T10:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00973479",
        "nct_id": "NCT00973479",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-23T12:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00488631",
        "nct_id": "NCT00488631",
        "studyTitle": "A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-01-04T14:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207714",
        "nct_id": "NCT00207714",
        "studyTitle": "A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-03-15T16:17:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00488774",
        "nct_id": "NCT00488774",
        "studyTitle": "A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-07T11:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01230827",
        "nct_id": "NCT01230827",
        "studyTitle": "A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T10:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02181673",
        "nct_id": "NCT02181673",
        "studyTitle": "A Study of Golimumab in Participants With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T10:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01004432",
        "nct_id": "NCT01004432",
        "studyTitle": "Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T10:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01863771",
        "nct_id": "NCT01863771",
        "studyTitle": "A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T11:00:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01988961",
        "nct_id": "NCT01988961",
        "studyTitle": "A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T11:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01962974",
        "nct_id": "NCT01962974",
        "studyTitle": "A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE\u00ae)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T11:19:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207740",
        "nct_id": "NCT00207740",
        "studyTitle": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-08-06T11:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01453725",
        "nct_id": "NCT01453725",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Also Known as MK-8259-006-02)",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-10-23T18:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02846545",
        "nct_id": "NCT02846545",
        "studyTitle": "SIMPONI\u00ae to Arrest \u03b2-cell Loss in Type 1 Diabetes",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03253796",
        "nct_id": "NCT03253796",
        "studyTitle": "Golimumab Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-10-14T20:55:44+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02277444",
        "nct_id": "NCT02277444",
        "studyTitle": "A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNF\u03b1 Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-04-29T20:20:54+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01483599",
        "nct_id": "NCT01483599",
        "studyTitle": "A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-02-27T14:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02207244",
        "nct_id": "NCT02207244",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-26T17:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02905331",
        "nct_id": "NCT02905331",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-27T14:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02951533",
        "nct_id": "NCT02951533",
        "studyTitle": "Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-27T14:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02207231",
        "nct_id": "NCT02207231",
        "studyTitle": "Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02325219",
        "nct_id": "NCT02325219",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03090100",
        "nct_id": "NCT03090100",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02203032",
        "nct_id": "NCT02203032",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03628924",
        "nct_id": "NCT03628924",
        "studyTitle": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-16T16:39:37+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03162796",
        "nct_id": "NCT03162796",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T16:59:52+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03158285",
        "nct_id": "NCT03158285",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T17:11:17+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02319759",
        "nct_id": "NCT02319759",
        "studyTitle": "A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T17:28:41+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03796858",
        "nct_id": "NCT03796858",
        "studyTitle": "Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF\u03b1) Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T17:33:34+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00316121",
        "nct_id": "NCT00316121",
        "studyTitle": "A Prospective, Multicenter, Randomized Study Comparing the Use of HEALOS\u00ae to Autograft in a Transforaminal Lumbar Interbody Fusion (TLIF) Approach",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-06T16:07:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01722487",
        "nct_id": "NCT01722487",
        "studyTitle": "Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-02-19T10:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01236391",
        "nct_id": "NCT01236391",
        "studyTitle": "Multicenter Phase 2 Study of Bruton\u2019s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-02-19T10:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01105247",
        "nct_id": "NCT01105247",
        "studyTitle": "A Phase 1b/2 Fixed-dose Study of Bruton\u2019s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-02-19T10:43:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01611090",
        "nct_id": "NCT01611090",
        "studyTitle": "Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-02-04T09:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02195869",
        "nct_id": "NCT02195869",
        "studyTitle": "A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02165397",
        "nct_id": "NCT02165397",
        "studyTitle": "iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenstr\u00f6m\u2019s Macroglobulinemia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01578707",
        "nct_id": "NCT01578707",
        "studyTitle": "A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02264574",
        "nct_id": "NCT02264574",
        "studyTitle": "A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-na\u00efve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-09T22:12:42+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01855750",
        "nct_id": "NCT01855750",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-02-05T19:35:37+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01776840",
        "nct_id": "NCT01776840",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-02-15T18:54:24+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01646021",
        "nct_id": "NCT01646021",
        "studyTitle": "A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-02-21T19:54:56+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01973387",
        "nct_id": "NCT01973387",
        "studyTitle": "A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-08T18:13:27+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02703272",
        "nct_id": "NCT02703272",
        "studyTitle": "A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-10-29T01:11:20+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "97-024",
        "nct_id": "97-024",
        "studyTitle": "Multiple-Dose Pharmacokinetic Study of an Ibuprofen-Psuedoephedrine HCl Suspension in Children. Aug 1999.",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-20T19:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "91-113",
        "nct_id": "91-113",
        "studyTitle": "Efficacy and pharmacokinetic/pharmacodynamic profile of ibuprofen chewable tablets versus ibuprofen suspension in febrile children. CSR 167S. Protocol 91-113, Unpublished Report 293A and Unpublished Report 1475.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-28T09:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00036374",
        "nct_id": "NCT00036374",
        "studyTitle": "A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00036439",
        "nct_id": "NCT00036439",
        "studyTitle": "A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00096655",
        "nct_id": "NCT00096655",
        "studyTitle": "A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207675",
        "nct_id": "NCT00207675",
        "studyTitle": "A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN\u2019S Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00094458",
        "nct_id": "NCT00094458",
        "studyTitle": "Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE\u00ae (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn\u2019s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn\u2019s Disease)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00336492",
        "nct_id": "NCT00336492",
        "studyTitle": "A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207662",
        "nct_id": "NCT00207662",
        "studyTitle": "ACCENT I \u2013 A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-04T14:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207766",
        "nct_id": "NCT00207766",
        "studyTitle": "ACCENT II \u2013 A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN\u2019S Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-04T14:11:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00004941",
        "nct_id": "NCT00004941",
        "studyTitle": "A Placebo-controlled, Repeated-dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Enterocutaneous Fistulae as a Complication of Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-04T14:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00269867",
        "nct_id": "NCT00269867",
        "studyTitle": "A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-04T14:18:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01551290",
        "nct_id": "NCT01551290",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-02-25T14:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01190839",
        "nct_id": "NCT01190839",
        "studyTitle": "Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn\u2019s Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-15T16:38:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00269854",
        "nct_id": "NCT00269854",
        "studyTitle": "A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-06-15T16:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207701",
        "nct_id": "NCT00207701",
        "studyTitle": "A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-09-08T14:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00036387",
        "nct_id": "NCT00036387",
        "studyTitle": "A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-09-10T11:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00060502",
        "nct_id": "NCT00060502",
        "studyTitle": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-01-16T16:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00073437",
        "nct_id": "NCT00073437",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-08T17:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00106834",
        "nct_id": "NCT00106834",
        "studyTitle": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00230529",
        "nct_id": "NCT00230529",
        "studyTitle": "A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE) Induction Therapy in Patients With Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00317538",
        "nct_id": "NCT00317538",
        "studyTitle": "Open-label, Pilot Protocol of Patients with Rheumatoid Arthritis Who Switch to Infliximab after Incomplete Response to Etanercept",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236028",
        "nct_id": "NCT00236028",
        "studyTitle": "A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:46:07+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00051623",
        "nct_id": "NCT00051623",
        "studyTitle": "A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-09T17:37:29+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00367237",
        "nct_id": "NCT00367237",
        "studyTitle": "A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX na\u00efve Subjects With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-05-15T19:45:01+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01497119",
        "nct_id": "NCT01497119",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects with Moderate Atopic Dermatitis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-30T16:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210886",
        "nct_id": "NCT00210886",
        "studyTitle": "A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-01-20T11:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00034736",
        "nct_id": "NCT00034736",
        "studyTitle": "A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-01-08T15:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00660179",
        "nct_id": "NCT00660179",
        "studyTitle": "A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-05-20T20:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01743001",
        "nct_id": "NCT01743001",
        "studyTitle": "A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T15:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00903331",
        "nct_id": "NCT00903331",
        "studyTitle": "A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T15:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02070991",
        "nct_id": "NCT02070991",
        "studyTitle": "A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T16:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01474109",
        "nct_id": "NCT01474109",
        "studyTitle": "Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-05T20:18:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01474122",
        "nct_id": "NCT01474122",
        "studyTitle": "Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-12-04T12:02:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02382016",
        "nct_id": "NCT02382016",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03359291",
        "nct_id": "NCT03359291",
        "studyTitle": "A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects.",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-11-21T21:06:52+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03153137",
        "nct_id": "NCT03153137",
        "studyTitle": "Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects (RUBATO DB)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-01-21T16:14:32+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03775421",
        "nct_id": "NCT03775421",
        "studyTitle": "Prospective, Multi-center, Single-arm, Open-label Long-term Study Assessing the Safety, Tolerability, and Effectiveness of Macitentan in Fontan-palliated Adult and Adolescent Subject (RUBATO OL)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-01-21T16:24:01+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02034162",
        "nct_id": "NCT02034162",
        "studyTitle": "A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-07T11:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01173562",
        "nct_id": "NCT01173562",
        "studyTitle": "An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-07T12:00:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02385058",
        "nct_id": "NCT02385058",
        "studyTitle": "Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-09-28T15:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00307684",
        "nct_id": "NCT00307684",
        "studyTitle": "An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:10:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00326300",
        "nct_id": "NCT00326300",
        "studyTitle": "An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00246220",
        "nct_id": "NCT00246220",
        "studyTitle": "A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T10:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00714688",
        "nct_id": "NCT00714688",
        "studyTitle": "A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-13T12:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00866996",
        "nct_id": "NCT00866996",
        "studyTitle": "A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00269815",
        "nct_id": "NCT00269815",
        "studyTitle": "Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00799409",
        "nct_id": "NCT00799409",
        "studyTitle": "The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-02-10T10:32:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00799487",
        "nct_id": "NCT00799487",
        "studyTitle": "Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-02-10T10:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00937040",
        "nct_id": "NCT00937040",
        "studyTitle": "A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-09T16:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00326391",
        "nct_id": "NCT00326391",
        "studyTitle": "A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-09-08T14:43:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01323192",
        "nct_id": "NCT01323192",
        "studyTitle": "A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-09-08T14:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00246233",
        "nct_id": "NCT00246233",
        "studyTitle": "A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA\u00ae (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-10-12T16:34:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01145625",
        "nct_id": "NCT01145625",
        "studyTitle": "A Phase 3, Multi-Center, Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam versus 2% Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01226459",
        "nct_id": "NCT01226459",
        "studyTitle": "A Phase 3, Multi-Center, Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam versus vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01156376",
        "nct_id": "NCT01156376",
        "studyTitle": "Determination of the oral irritation and sensitization potential of two experimental potassium oxalate containing mouth rinses",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01345292",
        "nct_id": "NCT01345292",
        "studyTitle": "Assessment of a potassium oxalate containing formulation for the relief of dentinal sensitivity",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01727258",
        "nct_id": "NCT01727258",
        "studyTitle": "Evaluation of an experimental mouth rinse device for relieving dentinal hypersenstivity",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02113579",
        "nct_id": "NCT02113579",
        "studyTitle": "Assessment of potassium oxalate containing formulation for the relief of dentinal hypersenstivity",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-31T10:34:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03896061",
        "nct_id": "NCT03896061",
        "studyTitle": "A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00816166",
        "nct_id": "NCT00816166",
        "studyTitle": "Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00553176",
        "nct_id": "NCT00553176",
        "studyTitle": "Crohn\u2019s Therapy, Resource, Evaluation, and Assessment Tool Registry",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-10-09T15:42:06+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00706082",
        "nct_id": "NCT00706082",
        "studyTitle": "A Two-stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2025-03-24T16:57:40+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236769",
        "nct_id": "NCT00236769",
        "studyTitle": "An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T17:01:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00745901",
        "nct_id": "NCT00745901",
        "studyTitle": "An Open Label Study to Evaluate Cycle Control with Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) and Yaz (drospirenone/ethinyl estradiol) in Healthy Sexually Active Females",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T17:06:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00488319",
        "nct_id": "NCT00488319",
        "studyTitle": "A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T11:08:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01009047",
        "nct_id": "NCT01009047",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T12:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00645099",
        "nct_id": "NCT00645099",
        "studyTitle": "A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T12:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00518323",
        "nct_id": "NCT00518323",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T12:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01606228",
        "nct_id": "NCT01606228",
        "studyTitle": "An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER among Treatment-Naive and Newly Diagnosed Patients with Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00334126",
        "nct_id": "NCT00334126",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00086320",
        "nct_id": "NCT00086320",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00650793",
        "nct_id": "NCT00650793",
        "studyTitle": "A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia \u2013 Open Label Phase",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00397033",
        "nct_id": "NCT00397033",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00412373",
        "nct_id": "NCT00412373",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:32:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00299715",
        "nct_id": "NCT00299715",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T10:25:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00309699",
        "nct_id": "NCT00309699",
        "studyTitle": "A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed, Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T10:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00309686",
        "nct_id": "NCT00309686",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T10:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00752427",
        "nct_id": "NCT00752427",
        "studyTitle": "24 week extension of NCT00085748: A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T10:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00077714",
        "nct_id": "NCT00077714",
        "studyTitle": "A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T10:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00083668",
        "nct_id": "NCT00083668",
        "studyTitle": "A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T11:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00078039",
        "nct_id": "NCT00078039",
        "studyTitle": "Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-27T09:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00085748",
        "nct_id": "NCT00085748",
        "studyTitle": "A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-01-22T08:48:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01662310",
        "nct_id": "NCT01662310",
        "studyTitle": "Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00490971",
        "nct_id": "NCT00490971",
        "studyTitle": "A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00524043",
        "nct_id": "NCT00524043",
        "studyTitle": "A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00105326",
        "nct_id": "NCT00105326",
        "studyTitle": "A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00645307",
        "nct_id": "NCT00645307",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS\u00ae Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia \u2013 Open Label Phase",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-07-18T12:48:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00460512",
        "nct_id": "NCT00460512",
        "studyTitle": "An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T11:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00566631",
        "nct_id": "NCT00566631",
        "studyTitle": "Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T11:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00668837",
        "nct_id": "NCT00668837",
        "studyTitle": "Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00589914",
        "nct_id": "NCT00589914",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00604279",
        "nct_id": "NCT00604279",
        "studyTitle": "A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects with Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-22T14:37:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00590577",
        "nct_id": "NCT00590577",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00111189",
        "nct_id": "NCT00111189",
        "studyTitle": "A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210717",
        "nct_id": "NCT00210717",
        "studyTitle": "A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00119756",
        "nct_id": "NCT00119756",
        "studyTitle": "A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210548",
        "nct_id": "NCT00210548",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00101634",
        "nct_id": "NCT00101634",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00074477",
        "nct_id": "NCT00074477",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-10-20T13:11:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01529515",
        "nct_id": "NCT01529515",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01193153",
        "nct_id": "NCT01193153",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01157351",
        "nct_id": "NCT01157351",
        "studyTitle": "A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:08:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01081769",
        "nct_id": "NCT01081769",
        "studyTitle": "A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01281527",
        "nct_id": "NCT01281527",
        "studyTitle": "A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:17:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01051531",
        "nct_id": "NCT01051531",
        "studyTitle": "Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01527305",
        "nct_id": "NCT01527305",
        "studyTitle": "An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01299389",
        "nct_id": "NCT01299389",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:46:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01258920",
        "nct_id": "NCT01258920",
        "studyTitle": "A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-27T18:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01515423",
        "nct_id": "NCT01515423",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T11:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02713282",
        "nct_id": "NCT02713282",
        "studyTitle": "A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-12-12T11:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03345342",
        "nct_id": "NCT03345342",
        "studyTitle": "A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01559272",
        "nct_id": "NCT01559272",
        "studyTitle": "A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00656097",
        "nct_id": "NCT00656097",
        "studyTitle": "A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-03-30T16:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00708084",
        "nct_id": "NCT00708084",
        "studyTitle": "A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-03-30T16:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01228383",
        "nct_id": "NCT01228383",
        "studyTitle": "A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-03-30T16:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT04068792",
        "nct_id": "NCT04068792",
        "studyTitle": "A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Study (Interventional Stage) to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 in Infants With Acute Respiratory Tract Infection Due to RSV",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-09T22:12:38+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03656510",
        "nct_id": "NCT03656510",
        "studyTitle": "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-11-15T17:29:45+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03379675",
        "nct_id": "NCT03379675",
        "studyTitle": "A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2024-11-15T17:36:40+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00540449",
        "nct_id": "NCT00540449",
        "studyTitle": "A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:07:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00543725",
        "nct_id": "NCT00543725",
        "studyTitle": "A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T16:09:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00391222",
        "nct_id": "NCT00391222",
        "studyTitle": "A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:40:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00034749",
        "nct_id": "NCT00034749",
        "studyTitle": "The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:43:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00076115",
        "nct_id": "NCT00076115",
        "studyTitle": "Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00132678",
        "nct_id": "NCT00132678",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00094926",
        "nct_id": "NCT00094926",
        "studyTitle": "A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236444",
        "nct_id": "NCT00236444",
        "studyTitle": "Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:34:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236470",
        "nct_id": "NCT00236470",
        "studyTitle": "Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders \u2013 an Open Label Follow-up Trial of CR002020",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00250354",
        "nct_id": "NCT00250354",
        "studyTitle": "The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00266552",
        "nct_id": "NCT00266552",
        "studyTitle": "The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00249132",
        "nct_id": "NCT00249132",
        "studyTitle": "A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-07-16T10:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216476",
        "nct_id": "NCT00216476",
        "studyTitle": "CONSTATRE: Risperdal\u00ae Consta\u00ae Trial of Relapse Prevention and Effectiveness",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-08-03T08:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216580",
        "nct_id": "NCT00216580",
        "studyTitle": "An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-08-03T08:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253162",
        "nct_id": "NCT00253162",
        "studyTitle": "The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-08-10T13:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00378092",
        "nct_id": "NCT00378092",
        "studyTitle": "A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-09-16T11:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00249158",
        "nct_id": "NCT00249158",
        "studyTitle": "Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:10:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00261508",
        "nct_id": "NCT00261508",
        "studyTitle": "Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:20:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00249236",
        "nct_id": "NCT00249236",
        "studyTitle": "The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00249145",
        "nct_id": "NCT00249145",
        "studyTitle": "Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00250367",
        "nct_id": "NCT00250367",
        "studyTitle": "The Safety And Efficacy Of Risperdal (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:26:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00088075",
        "nct_id": "NCT00088075",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253149",
        "nct_id": "NCT00253149",
        "studyTitle": "The Safety And Efficacy Of Risperdal (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:35:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253136",
        "nct_id": "NCT00253136",
        "studyTitle": "Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00034762",
        "nct_id": "NCT00034762",
        "studyTitle": "Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00257075",
        "nct_id": "NCT00257075",
        "studyTitle": "The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253123",
        "nct_id": "NCT00253123",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-03-31T12:44:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00246246",
        "nct_id": "NCT00246246",
        "studyTitle": "A Randomized, Open-label Trial of RISPERDAL\u00ae CONSTA\u2122 Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-11-02T12:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00044681",
        "nct_id": "NCT00044681",
        "studyTitle": "A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-24T12:58:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00249223",
        "nct_id": "NCT00249223",
        "studyTitle": "Risperidone Depot (Microspheres) vs. Risperidone Tablets \u2013 a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-03-08T14:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216671",
        "nct_id": "NCT00216671",
        "studyTitle": "Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:14:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00369239",
        "nct_id": "NCT00369239",
        "studyTitle": "Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:17:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216632",
        "nct_id": "NCT00216632",
        "studyTitle": "Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236379",
        "nct_id": "NCT00236379",
        "studyTitle": "A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:25:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00576732",
        "nct_id": "NCT00576732",
        "studyTitle": "Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01050582",
        "nct_id": "NCT01050582",
        "studyTitle": "Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00086112",
        "nct_id": "NCT00086112",
        "studyTitle": "A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-12-20T10:32:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216528",
        "nct_id": "NCT00216528",
        "studyTitle": "A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T09:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00269919",
        "nct_id": "NCT00269919",
        "studyTitle": "Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T10:01:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00992407",
        "nct_id": "NCT00992407",
        "studyTitle": "A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T10:04:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236353",
        "nct_id": "NCT00236353",
        "studyTitle": "An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T10:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00495118",
        "nct_id": "NCT00495118",
        "studyTitle": "Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder \u2013 an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T10:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01855074",
        "nct_id": "NCT01855074",
        "studyTitle": "Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:02:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236457",
        "nct_id": "NCT00236457",
        "studyTitle": "Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:05:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236587",
        "nct_id": "NCT00236587",
        "studyTitle": "An Open Label, Long Term Trial of Risperidone Long Acting Microspheres in the Treatment of Patients Diagnosed With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:09:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00297388",
        "nct_id": "NCT00297388",
        "studyTitle": "A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (RISPERDAL CONSTA) in Adults With Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00821600",
        "nct_id": "NCT00821600",
        "studyTitle": "Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia",
        "overallStatus": "",
        "phase": "Phase1",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00299702",
        "nct_id": "NCT00299702",
        "studyTitle": "A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal\u00ae Consta\u00ae and Abilify\u00ae (Aripiprazole) in Adults With Schizophrenia",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00526877",
        "nct_id": "NCT00526877",
        "studyTitle": "Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-03-18T11:41:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00061802",
        "nct_id": "NCT00061802",
        "studyTitle": "A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-07-26T13:45:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01624675",
        "nct_id": "NCT01624675",
        "studyTitle": "A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-07-26T14:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00034775",
        "nct_id": "NCT00034775",
        "studyTitle": "Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-10-25T10:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00095134",
        "nct_id": "NCT00095134",
        "studyTitle": "A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is not Responding to Standard Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2021-04-02T12:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01106014",
        "nct_id": "NCT01106014",
        "studyTitle": "A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-10-23T14:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02471183",
        "nct_id": "NCT02471183",
        "studyTitle": "Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-01-28T14:17:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02260557",
        "nct_id": "NCT02260557",
        "studyTitle": "A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud\u2019s Phenomenon Secondary to Systemic Sclerosis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-01-28T14:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03078907",
        "nct_id": "NCT03078907",
        "studyTitle": "A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient\u2019s Self-reported Symptoms and Their Impacts",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01604343",
        "nct_id": "NCT01604343",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-06T11:38:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01606761",
        "nct_id": "NCT01606761",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-06T11:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01689532",
        "nct_id": "NCT01689532",
        "studyTitle": "A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-28T19:29:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02019472",
        "nct_id": "NCT02019472",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA\u00ae Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-28T19:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01867164",
        "nct_id": "NCT01867164",
        "studyTitle": "A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-23T17:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210782",
        "nct_id": "NCT00210782",
        "studyTitle": "A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:53:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210535",
        "nct_id": "NCT00210535",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:55:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210860",
        "nct_id": "NCT00210860",
        "studyTitle": "An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-09-25T11:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00237289",
        "nct_id": "NCT00237289",
        "studyTitle": "Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00240721",
        "nct_id": "NCT00240721",
        "studyTitle": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-10-20T14:51:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236509",
        "nct_id": "NCT00236509",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:10:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231595",
        "nct_id": "NCT00231595",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:21:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236561",
        "nct_id": "NCT00236561",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:23:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216606",
        "nct_id": "NCT00216606",
        "studyTitle": "A Randomized Double-Blind Placebo Controlled Trial to Investigate the Efficacy and Tolerability of Topiramate in the Prophylaxis of Chronic Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00212810",
        "nct_id": "NCT00212810",
        "studyTitle": "TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:28:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210912",
        "nct_id": "NCT00210912",
        "studyTitle": "A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T08:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00037674",
        "nct_id": "NCT00037674",
        "studyTitle": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Two Doses of Topiramate for the Treatment of Acute Manic or Mixed Episodes in Patients With Bipolar I Disorder With an Optional Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T09:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00035230",
        "nct_id": "NCT00035230",
        "studyTitle": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2014-11-10T09:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00113815",
        "nct_id": "NCT00113815",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-10-12T16:31:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236639",
        "nct_id": "NCT00236639",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-22T13:37:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00216619",
        "nct_id": "NCT00216619",
        "studyTitle": "A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-22T13:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236600",
        "nct_id": "NCT00236600",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Patients Following Participation in an Intensive, Non-Pharmacologic Weight Loss Program",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-22T13:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231530",
        "nct_id": "NCT00231530",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet",
        "overallStatus": "",
        "phase": "",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-22T13:44:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236665",
        "nct_id": "NCT00236665",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-11-22T13:46:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210808",
        "nct_id": "NCT00210808",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-06-12T15:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00237302",
        "nct_id": "NCT00237302",
        "studyTitle": "A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2019-07-03T17:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210821",
        "nct_id": "NCT00210821",
        "studyTitle": "A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T15:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210496",
        "nct_id": "NCT00210496",
        "studyTitle": "Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T16:06:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231556",
        "nct_id": "NCT00231556",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T16:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231647",
        "nct_id": "NCT00231647",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROS Controlled-Release in the Treatment of Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T16:20:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231621",
        "nct_id": "NCT00231621",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, One-year Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Dyslipidemia",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T16:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236626",
        "nct_id": "NCT00236626",
        "studyTitle": "A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-05T16:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231660",
        "nct_id": "NCT00231660",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Treated With Metformin",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-06T10:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231634",
        "nct_id": "NCT00231634",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-06T10:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231608",
        "nct_id": "NCT00231608",
        "studyTitle": "The Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity: A 6-Month Double-Blind, Randomized, Placebo-Controlled Study With a 6-Month Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-06T10:56:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00035802",
        "nct_id": "NCT00035802",
        "studyTitle": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-06T11:08:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236418",
        "nct_id": "NCT00236418",
        "studyTitle": "Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-02-06T11:30:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00230698",
        "nct_id": "NCT00230698",
        "studyTitle": "Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T15:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00253175",
        "nct_id": "NCT00253175",
        "studyTitle": "A Comparison Of The Efficacy And Safety Of Topamax\u00ae (Topiramate) Tablets Versus Placebo For The Prophylaxis Of Migraine",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:02:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236704",
        "nct_id": "NCT00236704",
        "studyTitle": "Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:12:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236847",
        "nct_id": "NCT00236847",
        "studyTitle": "Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236756",
        "nct_id": "NCT00236756",
        "studyTitle": "A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236730",
        "nct_id": "NCT00236730",
        "studyTitle": "Double-Blind Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236873",
        "nct_id": "NCT00236873",
        "studyTitle": "Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T16:52:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236860",
        "nct_id": "NCT00236860",
        "studyTitle": "Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-26T17:08:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00236613",
        "nct_id": "NCT00236613",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-27T16:00:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210925",
        "nct_id": "NCT00210925",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-27T16:13:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00231673",
        "nct_id": "NCT00231673",
        "studyTitle": "A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Topiramate on Electrophysiological Parameters in Subjects With Diabetic Peripheral Polyneuropathy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-04-08T12:33:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02295865",
        "nct_id": "NCT02295865",
        "studyTitle": "A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:19+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01343277",
        "nct_id": "NCT01343277",
        "studyTitle": "A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-24T13:34:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00060944",
        "nct_id": "NCT00060944",
        "studyTitle": "A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-24T13:44:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00210665",
        "nct_id": "NCT00210665",
        "studyTitle": "A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-24T13:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00786838",
        "nct_id": "NCT00786838",
        "studyTitle": "A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-08-24T13:54:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00579501",
        "nct_id": "NCT00579501",
        "studyTitle": "Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-03-15T17:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00796120",
        "nct_id": "NCT00796120",
        "studyTitle": "An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-03-15T17:38:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01009086",
        "nct_id": "NCT01009086",
        "studyTitle": "A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-07-28T10:15:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01077362",
        "nct_id": "NCT01077362",
        "studyTitle": "A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2015-07-28T10:18:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00771667",
        "nct_id": "NCT00771667",
        "studyTitle": "A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn\u2019s Disease Previously Treated With TNF Antagonist Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-11-14T12:07:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01369329",
        "nct_id": "NCT01369329",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn\u2019s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-11-15T14:07:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01369342",
        "nct_id": "NCT01369342",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn\u2019s Disease (UNITI-2)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2016-11-15T14:09:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01369355",
        "nct_id": "NCT01369355",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-02-08T13:24:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00267969",
        "nct_id": "NCT00267969",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-05-08T16:57:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00307437",
        "nct_id": "NCT00307437",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2017-05-09T10:01:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00267956",
        "nct_id": "NCT00267956",
        "studyTitle": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-01-29T17:36:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01550744",
        "nct_id": "NCT01550744",
        "studyTitle": "A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a \u201cSubject-tailored\u201d Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T09:49:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00723528",
        "nct_id": "NCT00723528",
        "studyTitle": "A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T10:16:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00265122",
        "nct_id": "NCT00265122",
        "studyTitle": "A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T10:20:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00320216",
        "nct_id": "NCT00320216",
        "studyTitle": "A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T10:39:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00454584",
        "nct_id": "NCT00454584",
        "studyTitle": "A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T10:44:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00747344",
        "nct_id": "NCT00747344",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T11:42:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01008995",
        "nct_id": "NCT01008995",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T11:47:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01059773",
        "nct_id": "NCT01059773",
        "studyTitle": "An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)",
        "overallStatus": "",
        "phase": "Phase4",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T11:50:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01090427",
        "nct_id": "NCT01090427",
        "studyTitle": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS)",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-07-03T11:59:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02437162",
        "nct_id": "NCT02437162",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-09T15:14:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02438787",
        "nct_id": "NCT02438787",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF (Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-09T15:22:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02407223",
        "nct_id": "NCT02407223",
        "studyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2018-11-09T21:25:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00955279",
        "nct_id": "NCT00955279",
        "studyTitle": "A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2020-03-30T21:20:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT01645280",
        "nct_id": "NCT01645280",
        "studyTitle": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA\u00ae) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2022-04-06T12:01:00+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02698475",
        "nct_id": "NCT02698475",
        "studyTitle": "A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-07-27T05:12:24+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03464136",
        "nct_id": "NCT03464136",
        "studyTitle": "A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Na\u00efve Subjects With Moderately-to-Severely Active Crohn\u2019s Disease",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT03517722",
        "nct_id": "NCT03517722",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:44:39+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT00207727",
        "nct_id": "NCT00207727",
        "studyTitle": "A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase2",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-05T04:45:03+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": "NCT02407236",
        "nct_id": "NCT02407236",
        "studyTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase3",
        "studyType": "",
        "conditions": [],
        "orgCode": "",
        "orgName": "",
        "status": "",
        "postedDate": "2023-08-09T22:12:42+00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    }
]